Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients

(2016) Peter Alping et al.   ANNALS OF NEUROLOGY

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

Longterm Safety of Rituximab: Final Report of the Rheumatoid Arthritis Global Clinical Trial Program over 11 Years

(2015) R. F. van Vollenhoven et al.   JOURNAL OF RHEUMATOLOGY

Immunoglobulin M oligoclonal bands: Biomarker of targetable inflammation in primary progressive multiple sclerosis

(2014) Luisa M. Villar et al.   ANNALS OF NEUROLOGY

The Charcot Lecture | Beating MS: A story of B cells, with twists and turns

(2014) Stephen L Hauser   Multiple Sclerosis Journal

Acute jugular vein thrombosis during rituximab administration: Review of the literature

(2014) Reyad Dada et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with Clinically Isolated Syndrome

(2013) Diana Ferraro et al.   JOURNAL OF NEUROIMMUNOLOGY

Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression

(2013) Jeppe Romme Christensen et al.   PLoS One

Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review

(2013) Tamara Castillo-Trivino et al.   PLoS One

Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis

(2011) David B. Clifford   ARCHIVES OF NEUROLOGY

The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands

(2010) I. Boscá et al.   JOURNAL OF NEUROIMMUNOLOGY

Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM

(2010) Patrizia Sola et al.   Multiple Sclerosis Journal

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: A 52-week phase II trial

(2010) R. T. Naismith et al.   NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

FOUR NEW CASES OF THERAPY-RELATED ACUTE PROMYELOCYTIC LEUKEMIA AFTER MITOXANTRONE

(2008) I. Bosca et al.   NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE